Algorae Pharmaceuticals Expands Commercial Footprint with New Cadila Partnership

Like
Comment
Favorite

Algorae Pharmaceuticals Expands Commercial Footprint with New Cadila Partnership

Small Caps10-20

Algorae Pharmaceuticals (ASX: 1AI) and private Indian company Cadila Pharmaceuticals have entered into a licence and supply agreement covering two new generic medicines for the Australian and New ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2576600257?lang=en_US&edition=fundamental","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/10/Algorae-Pharmaceuticals-ASX-1AI-Expands-Commercial-Footprint-Cadila-Partnership.jpg","is_english":true,"pubTime":"2025-10-20 07:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576600257","market":"hk","top_or_hot":-1,"title":"Algorae Pharmaceuticals Expands Commercial Footprint with New Cadila Partnership","media":"Small Caps","content":"<div>\n<p>Algorae Pharmaceuticals (ASX: 1AI) and private Indian company Cadila Pharmaceuticals have entered into a licence and supply agreement covering two new generic medicines for the Australian and New ...</p>\n\n<a href=\"https://smallcaps.com.au/algorae-pharmaceuticals-expands-commercial-footprint-new-cadila-partnership/\">Source Link</a>\n\n</div>\n","source":"smallcap_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Algorae Pharmaceuticals Expands Commercial Footprint with New Cadila Partnership</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlgorae Pharmaceuticals Expands Commercial Footprint with New Cadila Partnership\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-20 07:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://smallcaps.com.au/algorae-pharmaceuticals-expands-commercial-footprint-new-cadila-partnership/><strong>Small Caps</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Algorae Pharmaceuticals (ASX: 1AI) and private Indian company Cadila Pharmaceuticals have entered into a licence and supply agreement covering two new generic medicines for the Australian and New ...</p>\n\n<a href=\"https://smallcaps.com.au/algorae-pharmaceuticals-expands-commercial-footprint-new-cadila-partnership/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://smallcaps.com.au/algorae-pharmaceuticals-expands-commercial-footprint-new-cadila-partnership/","article_id":"2576600257","we_media_id":null,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/10/Algorae-Pharmaceuticals-ASX-1AI-Expands-Commercial-Footprint-Cadila-Partnership.jpg"],"rights":{"source":"smallcap_stock","url":"https://smallcaps.com.au/algorae-pharmaceuticals-expands-commercial-footprint-new-cadila-partnership/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2576600257","pubTimestamp":1760918195,"columns":[],"sourceInfo":{"source_id":"smallcap_stock","name":"Small Caps"},"weMediaInfo":null,"summary":"Algorae Pharmaceuticals and private Indian company Cadila Pharmaceuticals have entered into a licence and supply agreement covering two new generic medicines for the Australian and New Zealand markets.The agreement will formalise an operational framework for the partnership and will see Algorae commence planning for Therapeutic Goods Administration  registration to enable commercialisation of the products, which will target key therapeutic areas including cardiovascular and metabolic disorders.Cadila operates manufacturing facilities in the US, UK, European Union, and Australia, and its products are distributed in over 100 countries, supported by a workforce of more than 9,000 professionals and a research and development division comprising more than 350 scientists.Algorae chief commercial officer Vishal Shah said the agreement would expand Algorae’s commercial footprint into new regions.“This deal represents an important step in executing our commercial strategy and expanding our prod","collect":0,"end_time":0,"defaultTopTitle":"smallcaps.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","XKO.AU":"标普/澳交所 300指数","EBO.AU":"EBOS GROUP LIMITED","BK7001":"电脑与电子产品零售","XAO.AU":"标普/澳交所 普通股指数","1AI.AU":"ALGORAE PHARMACEUTICALS LTD","TGA.AU":"Thorn GroupLtd","BK7103":"保健护理产品经销商","BK4213":"石油与天然气的勘探与生产","TGA":"Transglobe Energy Corp","XJO.AU":"标普/澳交所 200指数"},"translate_title":"Algorae Pharmaceuticals通过新的Cadila合作伙伴关系扩大商业足迹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBO.AU":1,"XAO.AU":0.78,"TGA":1,"XJO.AU":0.78,"1AI.AU":1,"XKO.AU":0.78,"TGA.AU":1},"content_text":"Algorae Pharmaceuticals (ASX: 1AI) and private Indian company Cadila Pharmaceuticals have entered into a licence and supply agreement covering two new generic medicines for the Australian and New Zealand markets.\nThe agreement will formalise an operational framework for the partnership and will see Algorae commence planning for Therapeutic Goods Administration (TGA) registration to enable commercialisation of the products, which will target key therapeutic areas including cardiovascular and metabolic disorders.\nCadila operates manufacturing facilities in the US, UK, European Union, and Australia, and its products are distributed in over 100 countries, supported by a workforce of more than 9,000 professionals and a research and development division comprising more than 350 scientists.\nExpanding Commercial Footprint\nAlgorae chief commercial officer Vishal Shah said the agreement would expand Algorae’s commercial footprint into new regions.\n“This deal represents an important step in executing our commercial strategy and expanding our product portfolio through a world-class manufacturing partner,” he said.\nAlgorae representatives recently met with senior management and technical teams at Cadila’s headquarters in Ahmedabad to secure the new agreement.\nCadila’s R&D department works across key therapeutic areas such as respiratory, cardiometabolic, gastrointestinal, oncology, anti-infective, and pain management.\n“With a diversified portfolio, strong regulatory track record, and commitment to sustainable growth, Cadila remains a trusted partner in improving access to healthcare worldwide,” Mr Shah added.\nExecutive Appointment\nAlgorae has appointed pharmaceutical executive David Gulland as chief operating officer to lead its operational and commercial scale-up initiatives.\nMr Gulland has more than 20 years of experience spanning private healthcare funding and pharmacy services—most recently as general manager of HPS Pharmacies, a division of Australasian pharmaceutical wholesaler and distributor EBOS Group (ASX: EBO).\nIn this role, he led enterprise-wide initiatives in digital transformation, supply chain optimisation and organisational restructuring, and pioneered Australia’s first private healthcare in-home funding model.\nMr Gulland will commence work with Algorae in March 2026.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}